Morgan Stanley's assumption of coverage with an Equal-Weight rating suggests a neutral outlook for Insulet's stock price in the short term. The price target of $343 indicates the analyst's expectation for the stock's future performance, but it does not guarantee any immediate impact on the stock price. The news is important for investors as it provides an updated perspective from a reputable financial institution, but the neutral rating does not suggest any significant short-term price movement.